Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencing

被引:20
|
作者
Nishimura, Adam A. [1 ]
Shirts, Brian H. [2 ]
Dorschner, Michael O. [2 ,3 ,4 ]
Amendola, Laura M. [5 ]
Smith, Joe W. [6 ]
Jarvik, Gail P. [3 ,5 ]
Tarczy-Hornoch, Peter [1 ,7 ,8 ]
机构
[1] Univ Washington, Dept Biomed Informat & Med Educ, Seattle, WA 98195 USA
[2] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[3] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA
[4] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
[5] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA
[6] Univ Washington, Sch Pharm, Seattle, WA 98195 USA
[7] Univ Washington, Dept Pediat, Seattle, WA 98195 USA
[8] Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
clinical decision support; clinical informatics; electronic medical records; genomic medicine; pharmacogenomics; RANDOMIZED-TRIAL; IMPLEMENTATION; MEDICINE; RECOMMENDATIONS; UNIVERSITY; DESIGN;
D O I
10.1038/gim.2015.5
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: Electronic health records (EHRs) and their associated decision support tools are potentially important means of disseminating a patient's pharmacogenomic profile to his or her health-care providers. We sought to create a proof-of-concept decision support alert system generated from pharmacogenomic incidental findings from exome sequencing. Methods: A pipeline for alerts from exome sequencing tests was created for patients in the New EXome Technology in (NEXT) Medicine study at the University of Washington. Decision support rules using discrete, machine-readable incidental finding results were programmed into a commercial EHR rules engine. An evaluation plan to monitor the alerts in real medical interactions was established. Results: Alerts were created for 48 actionable pharmacogenomic variants in 11 genes and were launched on 24 September 2014 for-University of Washington inpatient care. Of the 94 participants enrolled in the NEXT Medicine study, 49 had one or more pharmacogenomic variants identified for return. Conclusion: Reflections on the process reveal that while incidental findings can be used to generate decision support alerts, substantial resources are required to ensure that each alert is consistent with rapidly evolving pharmacogenomic literature and is customized to fit in the clinical workflow unique to each incidental finding.
引用
收藏
页码:939 / 942
页数:4
相关论文
共 50 条
  • [1] Incidental findings in clinical exome sequencing
    Yntema, H. G.
    van der Schoot, V.
    Haer-Wigman, L.
    Oerlemans, A. J. M.
    van Koolwijk, M.
    Tammer, F.
    Arens, Y.
    Brunner, H. G.
    Vissers, L. E. L. M.
    Feenstra, I.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1811 - 1812
  • [2] Patients' views on incidental findings from clinical exome sequencing
    Clift, Kristin E.
    Halverson, Colin M. E.
    Fiksdal, Alexander S.
    Kumbamu, Ashok
    Sharp, Richard R.
    McCormick, Jennifer B.
    APPLIED AND TRANSLATIONAL GENOMICS, 2015, 4 : 38 - 43
  • [3] Pharmacogenomic findings from clinical whole exome sequencing of diagnostic odyssey patients
    Cousin, Margot A.
    Matey, Eric T.
    Blackburn, Patrick R.
    Boczek, Nicole J.
    McAllister, Tammy M.
    Kruisselbrink, Teresa M.
    Babovic-Vuksanovic, Dusica
    Lazaridis, Konstantinos N.
    Klee, Eric W.
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2017, 5 (03): : 269 - 279
  • [4] The impact of incidental findings in clinical exome sequencing, a qualitative interview study
    van der Schoot, V.
    Viellevoije, S. J.
    Tammer, F.
    Brunner, H. G.
    Arens, Y.
    Yntema, H. G.
    Oerlemans, A. J. M.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 791 - 791
  • [5] ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing
    Green, Robert C.
    Berg, Jonathan S.
    Grody, Wayne W.
    Kalia, Sarah S.
    Korf, Bruce R.
    Martin, Christa L.
    McGuire, Amy L.
    Nussbaum, Robert L.
    O'Daniel, Julianne M.
    Ormond, Kelly E.
    Rehm, Heidi L.
    Watson, Michael S.
    Williams, Marc S.
    Biesecker, Leslie G.
    GENETICS IN MEDICINE, 2013, 15 (07) : 565 - 574
  • [6] Incidental and secondary findings in trio exome sequencing
    Cohen, Camille
    Bellanger, Emeline
    Mortreux, Jeremie
    Raymond, Laure
    Vialard, Francois
    Dard, Rodolphe
    GENES & DISEASES, 2024, 11 (04)
  • [7] Lessons learned from incidental findings in clinical exome sequencing of 16,482 individuals
    van der Schoot, Vyne
    Haer-Wigman, Lonneke
    Feenstra, Ilse
    Tammer, Femke
    Oerlemans, Anke J. M.
    van Koolwijk, Martine P. A.
    van Agt, Frans
    Arens, Yvonne H. J. M.
    Brunner, Han
    Vissers, Lissenka
    Ijntema, Helger G.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2022, 30 (SUPPL 1) : 577 - 577
  • [8] On the Justifiability of ACMG Recommendations for Reporting of Incidental Findings in Clinical Exome and Genome Sequencing
    May, Thomas
    JOURNAL OF LAW MEDICINE & ETHICS, 2015, 43 (01): : 134 - 142
  • [9] Not-so-incidental findings: the ACMG recommendations on the reporting of incidental findings in clinical whole genome and whole exome sequencing
    Allyse, Megan
    Michie, Marsha
    TRENDS IN BIOTECHNOLOGY, 2013, 31 (08) : 439 - 441
  • [10] IMPLEMENTATION OF PHARMACOGENOMIC CLINICAL DECISION SUPPORT ALERTS IN LEARNING HEALTH SYSTEMS: A COST-UTILITY ANALYSIS
    Jiang, S.
    Hendrix, N.
    Veenstra, D. L.
    Mathias, P.
    Devine, B.
    VALUE IN HEALTH, 2021, 24 : S69 - S70